{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:52:20Z","timestamp":1791291140033,"version":"4.3.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johnson & Johnson"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide\/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Here, we report an updated subgroup analysis by frailty status. We retrospectively performed frailty assessments using age, Charlson Comorbidity Index, and baseline Eastern Cooperative Oncology Group performance status score; patients were classified as fit, intermediate, non-frail (fit + intermediate), or frail. After a 64.5-month median follow-up, OS benefit of D-Rd versus Rd was maintained in the non-frail subgroup (median, not reached [NR] vs 69.8 months; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.37\u20130.76;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0004); the OS HR point estimate favored D-Rd versus Rd in the frail subgroup (NR vs 50.4 months; HR, 0.79; 95% CI, 0.58\u20131.06;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.1128). Improved PFS and rates of complete response or better and minimal residual disease negativity (10\n                    <jats:sup>\u20135<\/jats:sup>\n                    ) were observed with D-Rd versus Rd across frailty subgroups. Duration of therapy was consistently longer with D-Rd versus Rd, highlighting the improved disease control and long-term tolerability of daratumumab in frail patients. These long-term data, although limited by the retrospective assessment of frailty using baseline characteristics, continue to support the therapeutic benefit of D-Rd in terms of improved PFS and higher rates of deep responses in transplant-ineligible NDMM, regardless of frailty status.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-03128-5","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:05:58Z","timestamp":1791288358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-8460","authenticated-orcid":false,"given":"Thierry","family":"Facon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-0412","authenticated-orcid":false,"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-5161","authenticated-orcid":false,"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-2575","authenticated-orcid":false,"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-4796","authenticated-orcid":false,"given":"Supratik","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8300-1266","authenticated-orcid":false,"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjohn","family":"Armoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey","family":"Bolyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Borgsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3128_CR1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"3128_CR2","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"J Lammerts van Bueren","year":"2014","unstructured":"Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124:3474.","journal-title":"Blood"},{"key":"3128_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311\u201321.","journal-title":"MAbs"},{"key":"3128_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking. J Immunol. 2016;197:807\u201313.","journal-title":"J Immunol"},{"key":"3128_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"3128_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HCIII Adams","year":"2019","unstructured":"Adams HCIII, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, et al. High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytom A. 2019;95:279\u201389.","journal-title":"Cytom A"},{"key":"3128_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","volume":"35","author":"T Casneuf","year":"2021","unstructured":"Casneuf T, Adams HCIII, van de Donk NWCJ, Abraham Y, Bald J, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021;35:573\u201384.","journal-title":"Leukemia"},{"key":"3128_CR8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582\u201396.","journal-title":"Lancet Oncol"},{"key":"3128_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395:132\u201341.","journal-title":"Lancet"},{"key":"3128_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25:1003\u201314.","journal-title":"Lancet Oncol"},{"key":"3128_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"3128_CR12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study. Nat Med. 2025;31:1195\u2013202.","journal-title":"Nat Med"},{"key":"3128_CR13","unstructured":"DARZALEX (daratumumab) [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2025."},{"key":"3128_CR14","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"3128_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39:942\u201350.","journal-title":"Leukemia"},{"key":"3128_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224\u201333.","journal-title":"Leukemia"},{"key":"3128_CR17","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068\u201374.","journal-title":"Blood"},{"key":"3128_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980\u20137.","journal-title":"Haematologica"},{"key":"3128_CR19","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36:1066\u201377.","journal-title":"Leukemia"},{"key":"3128_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","volume":"21","author":"MV Mateos","year":"2021","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Knop S, Doyen C, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021;21:785\u201398.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3128_CR21","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.1200\/JCO.2019.37.15_suppl.8027","volume":"37","author":"MV Mateos","year":"2019","unstructured":"Mateos MV, Ludwig H, Kumar S, Rosenbaum CA, Huang M, Goldrick A, et al. Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 A.R.R.O.W. study. J Clin Oncol. 2019;37:8027.","journal-title":"J Clin Oncol"},{"key":"3128_CR22","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","volume":"4","author":"T Facon","year":"2020","unstructured":"Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, et al. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma. Blood Adv. 2020;4:5449\u201359.","journal-title":"Blood Adv"},{"key":"3128_CR23","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","volume":"34","author":"CAM Stege","year":"2020","unstructured":"Stege CAM, van der Holt B, Dinmohamed AG, Sonneveld P, Levin MD, van de Donk N, et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia. 2020;34:1964\u20136.","journal-title":"Leukemia."},{"key":"3128_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/ejh.14392","volume":"114","author":"A Perrot","year":"2025","unstructured":"Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, et al. Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes. Eur J Haematol. 2025;114:883\u20139.","journal-title":"Eur J Haematol"},{"key":"3128_CR25","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S1470-2045(25)00280-3","volume":"26","author":"S Manier","year":"2025","unstructured":"Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, et al. Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial. Lancet Oncol. 2025;26:1323\u201333.","journal-title":"Lancet Oncol"},{"key":"3128_CR26","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/blood.2020009507","volume":"137","author":"A Larocca","year":"2021","unstructured":"Larocca A, Bonello F, Gaidano G, D\u2019Agostino M, Offidani M, Cascavilla N, et al. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137:3027\u201336.","journal-title":"Blood"},{"key":"3128_CR27","doi-asserted-by":"crossref","unstructured":"Mian H, Facon T, Cook G, Moreau P, Usmani SZ, Kumar SK, et al. Dynamic frailty analysis of transplant-ineligible patients with NDMM in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone and bortezomib-Rd. Presented at the 22nd International Myeloma Society (IMS) Annual Meeting & Exposition; September 17\u201320, 2025; Toronto, ON, Canada.","DOI":"10.1016\/S2152-2650(25)03425-1"},{"key":"3128_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00843-5","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study. Blood Cancer J. 2023;13:76.","journal-title":"Blood Cancer J"},{"key":"3128_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1182\/blood.2024025868","volume":"145","author":"F Smits","year":"2025","unstructured":"Smits F, Groen K, Levin MD, Stege CAM, van Kampen R, van der Spek E, et al. Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma. Blood. 2025;145:543\u20136.","journal-title":"Blood"},{"key":"3128_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-024-01569-y","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liang X, Xu W, Yi X, Hu R, Ma X, et al. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study. J Hematol Oncol. 2024;17:48.","journal-title":"J Hematol Oncol"},{"key":"3128_CR31","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1097\/BS9.0000000000000208","volume":"6","author":"Y Dai","year":"2024","unstructured":"Dai Y, Jin F. Dynamic frailty-tailored therapy (DynaFiT): a proof-of-concept study in elderly patients with newly diagnosed multiple myeloma. Blood Sci. 2024;6:e00208.","journal-title":"Blood Sci"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03128-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03128-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03128-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:06:00Z","timestamp":1791288360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03128-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":31,"alternative-id":["3128"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03128-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TF has no competing interests to declare. GC received research support from Bristol Myers Squibb\/Celgene, Janssen, and Takeda; and served as a consultant for and received honoraria from Amgen, Bristol Myers Squibb\/Celgene, GSK, Janssen, Millennium\/Takeda, Oncopeptides, Roche, and Sanofi. SZU received grants from Amgen, Bristol Myers Squibb, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDx, and Takeda; and received personal fees from AbbVie, Amgen, Celgene, Genentech, Gilead, GSK, Janssen, Merck, Mundipharma, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, and Takeda. CH received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Janssen, and Pfizer. SK received research funding from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen Therapeutics, Janssen, Molecular Templates, Inc., Novartis, Roche\/Genentech, Takeda, and Teneobio, Inc.; and consulted for or participated on an advisory board for AbbVie, Amgen, Antengene, AstraZeneca, BeiGene, bluebird bio, Bristol Myers Squibb, Epizyme, Janssen, Oncopeptides, Roche-Genentech, Secura Bio, and Takeda. CT served on an advisory board for and received honoraria from Johnson & Johnson. NJB received research funding from Celgene, Janssen, and Pfizer; participated on an independent review committee for Janssen, Karyopharm, and Legend Biotech; received honoraria for educational events from Bristol Myers Squibb, Celgene, and Janssen; and participated on an advisory board for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, GSK, Janssen, Karyopharm, Pfizer, Sanofi, and Takeda. SB has no competing interests to declare. HG received grants or contracts from Bristol Myers Squibb, Celgene, Dietmar Hopp Foundation, Janssen, and Sanofi; received consulting fees from Bristol Myers Squibb, Janssen, and Sanofi; received payment or honoraria for lectures and presentations from Amgen, Bristol Myers Squibb, GSK, Janssen, Oncopeptides, Pfizer, and Sanofi; received support for attending meetings or travel, or both, from Amgen, Bristol Myers Squibb, GSK, Janssen, Oncopeptides, Pfizer, and Sanofi; and received research support from Amgen, Bristol Myers Squibb, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Janssen, Millennium, Novartis, Oncopeptides, Pfizer, and Sanofi. HQ received grants or contracts from AbbVie, Antengene, Bristol Myers Squibb, GSK, Karyopharm, and Sanofi; and had a leadership or fiduciary role in advisory boards for AbbVie, Antengene, Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, and Sanofi. MM received honoraria from Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, Sanofi, and Takeda; and received research funding from Celgene, Janssen, and Sanofi. CPV received honoraria from AbbVie, Amgen, Bristol Myers Squibb, FORUS Therapeutics Inc., GSK, Johnson & Johnson, Pfizer, Sanofi, and Takeda; and is a consultant for Paradox Immunotherapeutics. KW served in an advisory role or provided expert testimony for AbbVie, Adaptive Biotechnologies, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, CellCentric, GSK, Janssen, Karyopharm, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Stemline, and Takeda; received honoraria from AbbVie, Adaptive Biotechnologies, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, GSK, Janssen, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Stemline, and Takeda; and received grants from AbbVie (to the institution), Amgen (to the institution), Bristol Myers Squibb\/Celgene (to the institution), GSK (to the institution), Janssen (to the institution), and Sanofi (to the institution). NR served in an advisory role for Amgen, bluebird bio, Caribou, GSK, and Immuneel. SM received grant support, paid to Institut pour la Recherche sur le Cancer de Lille, from AbbVie; received grant support and advisory board fees, paid to Institut pour la Recherche sur le Cancer de Lille, from Amgen and Celgene; and received grant support, advisory board fees, paid to Journ\u00e9es d\u2019H\u00e9matologie Clinique Lilloises, and travel support from Janssen. MN is a contractor for Johnson & Johnson. MA is an employee of and holds stock in Johnson & Johnson. KB has a direct financial relationship with Amgen, Bristol Myers Squibb, Johnson & Johnson, Pfizer, and Sanofi. FB is an employee of and holds stock in Johnson & Johnson. RC is an employee of and holds stock in Johnson & Johnson. SZ received research support from Janssen and Takeda (paid to institution); and served on advisory boards for Amgen, Bristol Myers Squibb, GSK, Janssen, Oncopeptides, and Sanofi (all paid to institution).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}